HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $794,980 | +5.9% | 20,811 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $750,653 | -5.6% | 20,811 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $794,772 | -66.3% | 20,811 | -49.7% | 0.00% | -75.0% |
| Q4 2022 | $2,356,400 | +43.9% | 41,413 | 0.0% | 0.00% | +33.3% |
| Q3 2022 | $1,637,000 | -10.2% | 41,413 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $1,822,000 | +10.3% | 41,413 | 0.0% | 0.00% | +50.0% |
| Q1 2022 | $1,652,000 | -1.1% | 41,413 | -0.3% | 0.00% | 0.0% |
| Q4 2021 | $1,670,000 | -0.9% | 41,534 | +0.2% | 0.00% | 0.0% |
| Q3 2021 | $1,685,000 | -10.4% | 41,432 | +0.0% | 0.00% | -33.3% |
| Q2 2021 | $1,881,000 | -27.7% | 41,413 | -33.6% | 0.00% | -25.0% |
| Q1 2021 | $2,602,000 | -2.4% | 62,403 | -0.1% | 0.00% | -20.0% |
| Q4 2020 | $2,667,000 | +62.8% | 62,440 | +0.2% | 0.01% | +66.7% |
| Q3 2020 | $1,638,000 | +69.6% | 62,332 | +73.0% | 0.00% | +50.0% |
| Q2 2020 | $966,000 | +49.1% | 36,030 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $648,000 | +1.4% | 36,030 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $639,000 | +14.3% | 36,030 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $559,000 | -9.7% | 36,030 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $619,000 | -65.2% | 36,030 | -67.4% | 0.00% | -60.0% |
| Q1 2019 | $1,780,000 | +10.1% | 110,530 | 0.0% | 0.01% | 0.0% |
| Q4 2018 | $1,617,000 | -19.5% | 110,530 | 0.0% | 0.01% | -16.7% |
| Q3 2018 | $2,008,000 | +7.7% | 110,530 | 0.0% | 0.01% | 0.0% |
| Q2 2018 | $1,865,000 | -13.9% | 110,530 | 0.0% | 0.01% | -14.3% |
| Q1 2018 | $2,165,000 | -29.4% | 110,530 | -27.0% | 0.01% | -30.0% |
| Q4 2017 | $3,068,000 | -6.8% | 151,447 | -20.1% | 0.01% | -9.1% |
| Q3 2017 | $3,292,000 | +28.1% | 189,536 | -5.4% | 0.01% | +37.5% |
| Q2 2017 | $2,570,000 | -0.3% | 200,443 | +0.8% | 0.01% | -11.1% |
| Q1 2017 | $2,577,000 | +47.8% | 198,838 | +12.7% | 0.01% | +50.0% |
| Q4 2016 | $1,744,000 | -45.4% | 176,447 | -33.3% | 0.01% | -45.5% |
| Q3 2016 | $3,193,000 | +38.6% | 264,360 | -0.9% | 0.01% | +37.5% |
| Q2 2016 | $2,303,000 | +303.3% | 266,860 | +342.7% | 0.01% | +300.0% |
| Q1 2016 | $571,000 | – | 60,275 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |